Screener
Gilead Sciences GILD Other Liver Disease — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Europe | Three Months Ended June 30, 2026 / Rest of World | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Europe | Three Months Ended June 30, 2025 / Rest of World | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|
| Livdelzi | 147 | 20 | — | 167 | 74 | 4 | — | 78 |
| Sofosbuvir/Velpatasvir(3) | 142 | 81 | 80 | 303 | 184 | 81 | 76 | 342 |
| Vemlidy | 124 | 13 | 152 | 289 | 122 | 13 | 117 | 252 |
| Other Liver Disease(4) | 20 | 79 | 19 | 118 | 33 | 72 | 19 | 123 |
| Total Liver Disease | 433 | 193 | 251 | 877 | 413 | 170 | 211 | 795 |
| Veklury | 14 | 2 | 7 | 23 | 51 | 19 | 50 | 121 |
| Oncology | ||||||||
| Cell Therapy |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's other liver disease — total revenues?
- Gilead Sciences (GILD) reported other liver disease — total revenues of $118M in Q2 2026.
- How has Gilead Sciences's other liver disease — total revenues changed year-over-year?
- Gilead Sciences's other liver disease — total revenues decreased by 4.1% year-over-year, from $123M to $118M.
- What is the long-term trend for Gilead Sciences's other liver disease — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's other liver disease — total revenues has grown at a 21.1% compound annual growth rate (CAGR), from $426M to $756M.
- What does other liver disease — total revenues mean?
- This metric represents the total gross revenue generated from the sale of pharmaceutical products specifically categorized under the company's liver disease portfolio, excluding primary flagship franchises. It reflects the commercial performance and market adoption of secondary therapeutic assets targeting hepatic conditions. This revenue stream is a key indicator of the company's ability to diversify its specialized medicine portfolio beyond its core infectious disease franchises.
Ask your AI about Gilead Sciences's other liver disease — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude